Canine cancer immunotherapy studies

Linking mouse and human

Jiwon S. Park, Sita S. Withers, Jaime Modiano, Michael S. Kent, Mingyi Chen, Jesus I. Luna, William T.N. Culp, Ellen E. Sparger, Robert B. Rebhun, Arta M. Monjazeb, William J. Murphy, Robert J. Canter

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Despite recent major clinical breakthroughs in human cancer immunotherapy including the use of checkpoint inhibitors and engineered T cells, important challenges remain, including determining the sub-populations of patients who will respond and who will experience at times significant toxicities. Although advances in cancer immunotherapy depend on preclinical testing, the majority of in-vivo testing currently relies on genetically identical inbred mouse models which, while offering critical insights regarding efficacy and mechanism of action, also vastly underrepresent the heterogeneity and complex interplay of human immune cells and cancers. Additionally, laboratory mice uncommonly develop spontaneous tumors, are housed under specific-pathogen free conditions which markedly impacts immune development, and incompletely model key aspects of the tumor/immune microenvironment. The canine model represents a powerful tool in cancer immunotherapy research as an important link between murine models and human clinical studies. Dogs represent an attractive outbred combination of companion animals that experience spontaneous cancer development in the setting of an intact immune system. This allows for study of complex immune interactions during the course of treatment while also directly addressing long-term efficacy and toxicity of cancer immunotherapies. However, immune dissection requires access to robust and validated immune assays and reagents as well as appropriate numbers for statistical evaluation. Canine studies will need further optimization of these important mechanistic tools for this model to fulfill its promise as a model for immunotherapy. This review aims to discuss the canine model in the context of existing preclinical cancer immunotherapy models to evaluate both its advantages and limitations, as well as highlighting its growth as a powerful tool in the burgeoning field of both human and veterinary immunotherapy.

Original languageEnglish (US)
Article number97
JournalJournal for ImmunoTherapy of Cancer
Volume4
Issue number1
DOIs
StatePublished - Dec 20 2016

Fingerprint

Immunotherapy
Canidae
Neoplasms
Specific Pathogen-Free Organisms
Tumor Microenvironment
Pets
Antigen-Antibody Complex
Dissection
Immune System
Dogs
T-Lymphocytes
Growth
Research
Population

Keywords

  • Cancer immunotherapy
  • Canine model
  • Murine model
  • Outbred
  • Spontaneous cancer

Cite this

Park, J. S., Withers, S. S., Modiano, J., Kent, M. S., Chen, M., Luna, J. I., ... Canter, R. J. (2016). Canine cancer immunotherapy studies: Linking mouse and human. Journal for ImmunoTherapy of Cancer, 4(1), [97]. https://doi.org/10.1186/s40425-016-0200-7

Canine cancer immunotherapy studies : Linking mouse and human. / Park, Jiwon S.; Withers, Sita S.; Modiano, Jaime; Kent, Michael S.; Chen, Mingyi; Luna, Jesus I.; Culp, William T.N.; Sparger, Ellen E.; Rebhun, Robert B.; Monjazeb, Arta M.; Murphy, William J.; Canter, Robert J.

In: Journal for ImmunoTherapy of Cancer, Vol. 4, No. 1, 97, 20.12.2016.

Research output: Contribution to journalReview article

Park, JS, Withers, SS, Modiano, J, Kent, MS, Chen, M, Luna, JI, Culp, WTN, Sparger, EE, Rebhun, RB, Monjazeb, AM, Murphy, WJ & Canter, RJ 2016, 'Canine cancer immunotherapy studies: Linking mouse and human', Journal for ImmunoTherapy of Cancer, vol. 4, no. 1, 97. https://doi.org/10.1186/s40425-016-0200-7
Park, Jiwon S. ; Withers, Sita S. ; Modiano, Jaime ; Kent, Michael S. ; Chen, Mingyi ; Luna, Jesus I. ; Culp, William T.N. ; Sparger, Ellen E. ; Rebhun, Robert B. ; Monjazeb, Arta M. ; Murphy, William J. ; Canter, Robert J. / Canine cancer immunotherapy studies : Linking mouse and human. In: Journal for ImmunoTherapy of Cancer. 2016 ; Vol. 4, No. 1.
@article{59400329a43b4cfd8f8aa4a49a959175,
title = "Canine cancer immunotherapy studies: Linking mouse and human",
abstract = "Despite recent major clinical breakthroughs in human cancer immunotherapy including the use of checkpoint inhibitors and engineered T cells, important challenges remain, including determining the sub-populations of patients who will respond and who will experience at times significant toxicities. Although advances in cancer immunotherapy depend on preclinical testing, the majority of in-vivo testing currently relies on genetically identical inbred mouse models which, while offering critical insights regarding efficacy and mechanism of action, also vastly underrepresent the heterogeneity and complex interplay of human immune cells and cancers. Additionally, laboratory mice uncommonly develop spontaneous tumors, are housed under specific-pathogen free conditions which markedly impacts immune development, and incompletely model key aspects of the tumor/immune microenvironment. The canine model represents a powerful tool in cancer immunotherapy research as an important link between murine models and human clinical studies. Dogs represent an attractive outbred combination of companion animals that experience spontaneous cancer development in the setting of an intact immune system. This allows for study of complex immune interactions during the course of treatment while also directly addressing long-term efficacy and toxicity of cancer immunotherapies. However, immune dissection requires access to robust and validated immune assays and reagents as well as appropriate numbers for statistical evaluation. Canine studies will need further optimization of these important mechanistic tools for this model to fulfill its promise as a model for immunotherapy. This review aims to discuss the canine model in the context of existing preclinical cancer immunotherapy models to evaluate both its advantages and limitations, as well as highlighting its growth as a powerful tool in the burgeoning field of both human and veterinary immunotherapy.",
keywords = "Cancer immunotherapy, Canine model, Murine model, Outbred, Spontaneous cancer",
author = "Park, {Jiwon S.} and Withers, {Sita S.} and Jaime Modiano and Kent, {Michael S.} and Mingyi Chen and Luna, {Jesus I.} and Culp, {William T.N.} and Sparger, {Ellen E.} and Rebhun, {Robert B.} and Monjazeb, {Arta M.} and Murphy, {William J.} and Canter, {Robert J.}",
year = "2016",
month = "12",
day = "20",
doi = "10.1186/s40425-016-0200-7",
language = "English (US)",
volume = "4",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Canine cancer immunotherapy studies

T2 - Linking mouse and human

AU - Park, Jiwon S.

AU - Withers, Sita S.

AU - Modiano, Jaime

AU - Kent, Michael S.

AU - Chen, Mingyi

AU - Luna, Jesus I.

AU - Culp, William T.N.

AU - Sparger, Ellen E.

AU - Rebhun, Robert B.

AU - Monjazeb, Arta M.

AU - Murphy, William J.

AU - Canter, Robert J.

PY - 2016/12/20

Y1 - 2016/12/20

N2 - Despite recent major clinical breakthroughs in human cancer immunotherapy including the use of checkpoint inhibitors and engineered T cells, important challenges remain, including determining the sub-populations of patients who will respond and who will experience at times significant toxicities. Although advances in cancer immunotherapy depend on preclinical testing, the majority of in-vivo testing currently relies on genetically identical inbred mouse models which, while offering critical insights regarding efficacy and mechanism of action, also vastly underrepresent the heterogeneity and complex interplay of human immune cells and cancers. Additionally, laboratory mice uncommonly develop spontaneous tumors, are housed under specific-pathogen free conditions which markedly impacts immune development, and incompletely model key aspects of the tumor/immune microenvironment. The canine model represents a powerful tool in cancer immunotherapy research as an important link between murine models and human clinical studies. Dogs represent an attractive outbred combination of companion animals that experience spontaneous cancer development in the setting of an intact immune system. This allows for study of complex immune interactions during the course of treatment while also directly addressing long-term efficacy and toxicity of cancer immunotherapies. However, immune dissection requires access to robust and validated immune assays and reagents as well as appropriate numbers for statistical evaluation. Canine studies will need further optimization of these important mechanistic tools for this model to fulfill its promise as a model for immunotherapy. This review aims to discuss the canine model in the context of existing preclinical cancer immunotherapy models to evaluate both its advantages and limitations, as well as highlighting its growth as a powerful tool in the burgeoning field of both human and veterinary immunotherapy.

AB - Despite recent major clinical breakthroughs in human cancer immunotherapy including the use of checkpoint inhibitors and engineered T cells, important challenges remain, including determining the sub-populations of patients who will respond and who will experience at times significant toxicities. Although advances in cancer immunotherapy depend on preclinical testing, the majority of in-vivo testing currently relies on genetically identical inbred mouse models which, while offering critical insights regarding efficacy and mechanism of action, also vastly underrepresent the heterogeneity and complex interplay of human immune cells and cancers. Additionally, laboratory mice uncommonly develop spontaneous tumors, are housed under specific-pathogen free conditions which markedly impacts immune development, and incompletely model key aspects of the tumor/immune microenvironment. The canine model represents a powerful tool in cancer immunotherapy research as an important link between murine models and human clinical studies. Dogs represent an attractive outbred combination of companion animals that experience spontaneous cancer development in the setting of an intact immune system. This allows for study of complex immune interactions during the course of treatment while also directly addressing long-term efficacy and toxicity of cancer immunotherapies. However, immune dissection requires access to robust and validated immune assays and reagents as well as appropriate numbers for statistical evaluation. Canine studies will need further optimization of these important mechanistic tools for this model to fulfill its promise as a model for immunotherapy. This review aims to discuss the canine model in the context of existing preclinical cancer immunotherapy models to evaluate both its advantages and limitations, as well as highlighting its growth as a powerful tool in the burgeoning field of both human and veterinary immunotherapy.

KW - Cancer immunotherapy

KW - Canine model

KW - Murine model

KW - Outbred

KW - Spontaneous cancer

UR - http://www.scopus.com/inward/record.url?scp=85006822901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006822901&partnerID=8YFLogxK

U2 - 10.1186/s40425-016-0200-7

DO - 10.1186/s40425-016-0200-7

M3 - Review article

VL - 4

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 97

ER -